The effect of sucralfate on the bioavailability of ciprofloxacin was evaluated in eight healthy subjects utilizing a randomized, crossover design. The area under the concentration-time curve from 0 to 12 h was reduced from 8.8 to 1.1 ,ug * h/ml by sucralfate (P < 0.005). Similarly, the maximum concentration of ciprofloxacin in serum was reduced from 2.0 to 0.2 ,ug/ml (P < 0.005). We condude that concurrent ingestion of sucralfate significantly reduces the concentrations in serum produced by a 500-mg dose of ciprofloxacin. On the basis of these findings, ciprofloxacin and sucralfate should not be administered concurrently. Inc.; lot BEA 9) with 240 ml of water, following an overnight fast, at 7 a.m. Subjects assigned to treatment B took 1 g of sucralfate (Carafate; Marion Laboratories; lot R8395) four times a day, 30 min before meals and at bedtime, on the day prior to the study. They then received ciprofloxacin (500 mg) and sucralfate (1 g), along with 240 ml of water, at 7 a.m. on the day of the study. Breakfast was provided to all subjects on the day of the study at 9 a.m.
Sucralfate, which contains 16 aluminum ions per molecule, is widely used in the treatment of peptic ulcer disease and other gastrointestinal disorders (3) . Once dissolution occurs in the stomach, aluminum is released from the molecule, as was evidenced by an increase in aluminum concentrations in serum and urinary excretion (5, 7, 9) . Sucralfate has recently been reported to significantly impair the absorption of norfloxacin, another fluoroquinolone (8) . Relative bioavailability when the two agents were taken concomitantly was reduced to 1.8%. Even when norfloxacin was administered 2 h after sucralfate, relative bioavailability was only 56.6%.
The objective of this study was to determine whether concurrent administration of sucralfate and ciprofloxacin reduced the bioavailability of ciprofloxacin, as measured by the area under the concentration-versus-time curve (AUC).
Eight healthy subjects (six males) were recruited to participate in the study. The Standard concentrations of 0.1, 1, 2, 3, 4, 5, and 10 ,ug/ml were prepared by diluting a 1,000-,ug/ml ciprofloxacin stock solution with pooled blood bank serum. A calibration curve was constructed by a least-squares linear regression analysis of peak height versus concentration. The intra-and interassay coefficients of variation were 2.5 and 5.0o, respectively. The interday coefficients of variation were 1.7% at 10 ,ug/ml and 6.4% at 0.1 pug/ml. The assay was able to accurately detect concentrations of ciprofloxacin in serum as low as 0.1 ,ug/ml. Table 1 shows the individual values for AUCO.12 for subjects receiving treatments A and B. The AUCs were lower in all subjects when they took sucralfate plus ciprofloxacin as compared with when they took ciprofloxacin alone. The AUCs were decreased to such a great extent when the subjects took sucralfate that concentrations in serum were frequently beneath the reliable sensitivity of the assay. The mean AUCsO-12 were significantly different (P < 0.005) between treatments A and B ( Table 2) . The large magnitude of this difference could also be seen when the Cm., values of the two treatments were compared (P < 0.005), while the Tm. showed no significant difference.
Actual plots of the mean concentration-time data of each treatment are shown in Fig. 1, which (Table 2) in our subjects who took ciprofloxacin alone were very similar to parameters reported by other investigators (1, 2, 4) . The effect of sucralfate on ciprofloxacin absorption was very consistent and produced marked changes in pharmacokinetic parameters when compared with the effects of ciprofloxacin alone. No subject achieved a Cm. greater than 0.4 ,ug/ml; in five of the eight subjects, the Cm. was 0.2 jig/ml.
One of the subjects, during the interaction phase, did not have detectable concentrations of ciprofloxacin at any time.
In contrast, there was a great deal of variability in Tm. with nearly constant, concentrations of ciprofloxacin in serum achieved throughout the 12-h sampling period, it appears that coadministration of sucralfate also slows the rate of absorption of ciprofloxacin. It is unknown whether the binding between ciprofloxacin and sucralfate is reversible, although this would not be expected if complexation between the two molecules occurs. We cannot rule out continued absorption of ciprofloxacin past 12 h. However, this seems unlikely, as six of the eight subjects receiving treatment B had undetectable concentrations of ciprofloxacin in serum at 12 h. Because of the close approximation of these concentrations of ciprofloxacin in serum to the limit of detectability of the assay, it would be very difficult to determine whether continued absorption was occurring.
It has recently been reported that administration of sucralfate 6 and 2 h prior to administration of ciprofloxacin results in a 30% reduction in bioavailability (6) . A decrease of more than 50%1o was noted in one-third of the subjects in that study.
The question still remains as to what would happen if ciprofloxacin was given 2 h before sucralfate, instead of vice versa. Since Tmax occurs early in most patients (1.4 + 0.3 h in our study), perhaps this would allow extensive absorption to occur before sucralfate is administered. Since this would result in administration of ciprofloxacin 4 h after the previous dose of sucralfate (when it is being given every 6 h), this time interval should also be studied.
In summary, ciprofloxacin and sucralfate should not be administered concurrently. A significant reduction in bioavailability occurs with this combination, with the likelihood of therapeutic failure, especially for moderately susceptible bacteria. Additional work is necessary to evaluate alternative dosing strategies to minimize or avoid this interaction. 
